Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IMGN779 |
Synonyms | |
Therapy Description |
IMGN779 is an anti-CD33 antibody in conjugation with a DNA-alkylating agent DGN-462, which delivers cytotoxicity to CD33-positive tumor cells (Blood 2014 124:2321, PMID: 29588393, PMID: 31115909, PMID: 31413807). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMGN779 | IMGN-779|IMGN 779 | CD33 Antibody 13 | IMGN779 is an anti-CD33 antibody in conjugation with a DNA-alkylating agent DGN-462, which delivers cytotoxicity to CD33-positive tumor cells (Blood 2014 124:2321, PMID: 29588393, PMID: 31115909, PMID: 31413807). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02674763 | Phase I | IMGN779 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | Completed | USA | 0 |